CCS
AMED

Crosspoint Capital Strategies’s Amedisys AMED Stock Holding History

Crosspoint Capital Strategies’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-272
Closed -$11K – 756
2015
Q2 		$11K Buy
+272
New +$8.47K ﹤0.01% 475

Other funds holding AMED

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Crosspoint Capital Strategies's AMED Position: Q3 2015 in Review

Crosspoint Capital Strategies sold out of Amedisys (AMED) in Q3 2015, closing a stake of 272 shares — an estimated $11K sold.

Crosspoint Capital Strategies first reported a position in AMED in Q2 2015 and held it in 1 quarter. The position peaked at $11K in Q2 2015. 173 funds tracked by Wall St. Rank hold AMED as of Q3 2015.

  • Crosspoint Capital Strategies reported no remaining Amedisys position as of Q3 2015 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 272 Amedisys shares in Q3 2015, an estimated $11K.
  • Crosspoint Capital Strategies first reported a position in Amedisys in Q2 2015 and held it in 1 quarter.
  • Crosspoint Capital Strategies's Amedisys position peaked at $11K in Q2 2015.
  • 173 funds tracked by Wall St. Rank held Amedisys as of Q3 2015.

Based on Crosspoint Capital Strategies's 13F filing for Q3 2015, filed 25 Nov 2015.